SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-009590
Filing Date
2022-05-12
Accepted
2022-05-12 14:23:05
Documents
52
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q lrmr-20220331.htm   iXBRL 10-Q 1388160
2 EX-31.1 lrmr-ex31_1.htm EX-31.1 13670
3 EX-31.2 lrmr-ex31_2.htm EX-31.2 13791
4 EX-32.1 lrmr-ex32_1.htm EX-32.1 23341
  Complete submission text file 0000950170-22-009590.txt   5501116

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lrmr-20220331_pre.xml EX-101.PRE 232310
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lrmr-20220331_lab.xml EX-101.LAB 327044
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lrmr-20220331_def.xml EX-101.DEF 122387
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT lrmr-20220331_cal.xml EX-101.CAL 32521
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lrmr-20220331.xsd EX-101.SCH 36524
46 EXTRACTED XBRL INSTANCE DOCUMENT lrmr-20220331_htm.xml XML 985051
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36510 | Film No.: 22917190
SIC: 2834 Pharmaceutical Preparations